Insulin detemir - Biologic Drug Details

✉ Email this page to a colleague

Summary for insulin detemir

Tradenames:	1
High Confidence Patents:	14
Applicants:	1
BLAs:	1
Suppliers: see list	2
Recent Clinical Trials:	See clinical trials for insulin detemir
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for insulin detemir

Recent Clinical Trials for insulin detemir

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
University of California, Los Angeles	Phase 2
First Affiliated Hospital Xi'an Jiaotong University	N/A
Minneapolis Medical Research Foundation	N/A

See all insulin detemir clinical trials

Recent Litigation for insulin detemir

Identify key patents and potential future biosimilar entrants

District Court Litigation

Case Name	Date
Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC	2021-11-10
Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC	2021-05-12
Par Pharmaceutical, Inc. v. Eagle Pharmaceuticals, Inc.	2018-05-31

See all insulin detemir litigation

Pharmacology for insulin detemir

Ingredient-type	Insulin
Established Pharmacologic Class	Insulin Analog

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for insulin detemir Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for insulin detemir Derived from Company Disclosures

These patents were obtained from company disclosures

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novo Nordisk Inc.	LEVEMIR	insulin detemir	Injection	021536	⤷ Sign Up	2026-07-17	Company disclosures
Novo Nordisk Inc.	LEVEMIR	insulin detemir	Injection	021536	⤷ Sign Up	2037-11-17	Company disclosures
Novo Nordisk Inc.	LEVEMIR	insulin detemir	Injection	021536	⤷ Sign Up	2037-02-24	Company disclosures
Novo Nordisk Inc.	LEVEMIR	insulin detemir	Injection	021536	⤷ Sign Up	2039-01-17	Company disclosures
Novo Nordisk Inc.	LEVEMIR	insulin detemir	Injection	021536	⤷ Sign Up		Company disclosures
Novo Nordisk Inc.	LEVEMIR	insulin detemir	Injection	021536	⤷ Sign Up	2008-02-10	Company disclosures
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Patent No.	>Estimated Patent Expiration	>Source

3) Low Certainty: US Patents for insulin detemir Derived from Patent Text Search

These patents were obtained by searching patent claims